The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A retrospective study of anlotinib plus third-generation EGFR-TKIs in advanced non-small cell lung cancer with gradual or oligo progression after EGFR-TKIs treatment (ALTER-L058).
 
Caicun Zhou
Leadership - IASLC BOD
Honoraria - Anheart Therapeutics; Hengrui Therapeutics; Lilly; Luye Pharma; Merck Sharpe and Dohme; MSD; QiLu Pharmaceutical; Sanofi
Consulting or Advisory Role - Innovent Biologics
 
Fei Zhou
Speakers' Bureau - BeiGene; Hengrui Therapeutics; Merck; Pfizer; QiLu Pharmaceutical; Roche China
 
Hongmin Wang
No Relationships to Disclose
 
Minglei Zhuo
No Relationships to Disclose
 
Nong Yang
No Relationships to Disclose
 
Jisheng Li
No Relationships to Disclose
 
Shi Jin
No Relationships to Disclose
 
Zhengxiang Han
No Relationships to Disclose
 
Guilin Zeng
No Relationships to Disclose
 
Jun Liu
No Relationships to Disclose
 
Yang Song
No Relationships to Disclose
 
Haitao Liu
No Relationships to Disclose
 
Lufang Wang
No Relationships to Disclose
 
Ling Li
No Relationships to Disclose
 
Jian Chen
No Relationships to Disclose
 
Jinghui Bai
No Relationships to Disclose
 
Fengming Ran
No Relationships to Disclose